Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Jasmine Ito"'
Autor:
Glaivy Batsuli, Jasmine Ito, Elizabeth S. York, Courtney Cox, Wallace Baldwin, Surinder Gill, Pete Lollar, Shannon L. Meeks
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
IntroductionSoluble antigens complexed with immunoglobulin G (IgG) antibodies can induce robust adaptive immune responses in vitro and in animal models of disease. Factor VIII immune complexes (FVIII-ICs) have been detected in individuals with hemoph
Externí odkaz:
https://doaj.org/article/a70c76ed1368497d958ddeddbe725018
Autor:
Glaivy Batsuli, John F. Healey, Ernest T. Parker, W. Hunter Baldwin, Jasmine Ito, Emily R. Legan, Surinder Gill, Renhao Li, Courtney Cox
Publikováno v:
J Thromb Haemost
BACKGROUND: A portion of individuals with hemophilia A develop neutralizing antibodies called inhibitors to glycoprotein factor VIII (FVIII). There are multiple risk factors that contribute to the risk of inhibitor formation. However, knowledge of th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::943f6d08a17651e390a434830c309e7c
https://doi.org/10.1111/jth.15616
https://doi.org/10.1111/jth.15616
Autor:
Ernest T. Parker, John F. Healey, Wallace Hunter Baldwin, Glaivy Batsuli, Shannon L. Meeks, Pete Lollar, R. Mercer, Courtney Cox, Jasmine Ito
Publikováno v:
Journal of thrombosis and haemostasis : JTH. 16(9)
Essentials Inhibitor formation remains a challenging complication of hemophilia A care. The Bethesda assay is the primary method used for determining bleeding risk and management. Antibodies that block factor VIII binding to von Willebrand factor can
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ff8900c7a9bcdcee3448ae39c654619
https://pubmed.ncbi.nlm.nih.gov/29981270
https://pubmed.ncbi.nlm.nih.gov/29981270
Publikováno v:
Blood. 128:3772-3772
Introduction: Up to 30% of patients with severe hemophilia A will develop inhibitory antibodies to factor VIII (fVIII inhibitors). Patients with congenital hemophilia who develop inhibitors usually have a polyclonal antibody response directed against
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8c4361160d103fa382795a87ff962d2e
https://doi.org/10.1182/blood.v128.22.3772.3772
https://doi.org/10.1182/blood.v128.22.3772.3772